Sofosbuvir + simeprevir dual therapy shows high cure rates for hepatitis C patients with or without cirrhosis
European liver specialists recommend 'mix-and-match' approach to new hepatitis C drugs
Sofosbuvir/ledipasvir produces early cure for 100% of people with HIV and HCV co-infection
Sofosbuvir/ledipasvir is safe and effective for relapsers and hard-to-treat patients
88% of previous relapsers achieve hepatitis C cure with simeprevir-based triple therapy
AbbVie interferon-free regimen cures 96% of treatment-experienced genotype 1 hepatitis C infections
Can we provide point-of-care viral load tests in poor countries?
PROUD UK PrEP study completes enrolment – first data give participants' background and risk factors
WHO recommends global use of newest hepatitis C drugs, urges price reductions
